Sandra Heskamp, Yvonne Derks and colleagues, developed a novel PSMA-targeting ligand, optimized for multimodal image-guided PCa surgery combined with targeted photodynamic therapy and published the these findings in the Theranostics.
Incomplete resection of prostate cancer (PCa) occurs in 15%-50% of patients, which can lead to disease recurrence. To improve outcome for PCa patients, new approaches to increase the chance of complete resection of all tumor tissue is required. PCa cells are characterized by overexpression of prostate-specific membrane antigen (PSMA). PSMA targeting ligands labeled with both a radionuclide and photosensitizer can potentially be used to improve intra-operative PCa detection and treatment.
Here, we developed and characterized dual labeled [111In]In-DOTA(GA)-IRDye700DX-PSMA ligands, varying in their molecular composition, for use in intraoperative radiodetection, fluorescence imaging and targeted photodynamic therapy of PCa lesions. PSMA-specificity of these ligands was determined in xenograft tumor models and on fresh human PCa biopsies.
Ligand structure optimization showed that addition of the photosensitizer (IRDye700DX) and additional negative charges significantly increased ligand uptake in PSMA-expressing tumors. Moreover, an ex vivo incubation study on human tumor biopsies confirmed the PSMA-specificity of these ligands on human samples, bridging the gap to the clinical situation.
We developed a novel PSMA-targeting ligand, optimized for multimodal image-guided PCa surgery combined with targeted photodynamic therapy. Currently, we are in the preparatory phase of producing this dual-labelled PSMA ligand for clinical use in PCa patients.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
How much should we exercise to live healthier lives? Research into the relationship between exercise, heart disease and mortality3 December 2021
It has long been known that exercise reduces the risk of many chronic diseases. However, we do not yet know exactly how much exercise is necessary to achieve health benefit.read more
KNAW Early Career Award for Martine Hoogman2 December 2021
Martine Hoogman has been awarded a KNAW Early Career Award. The prize, a sum of 15,000 euros and a work of art, is aimed at researchers in the Netherlands who are at the start of their careers and have innovative, original research ideas.read more
T-Guard can reset immune system1 December 2021
For 20 years, the Nijmegen based Radboudumc spin-off company Xenikos has been working on a drug that can reset the immune system. This reset will save lives of seriously ill patients. Now, after years of hard work, the moment of truth has arrived for T-guard.read more
Thomas van den Heuvel wins Stairway to Impact Award for safer pregnancies using AI Award for safer pregnancies using AI1 December 2021
Radboudumc researcher Thomas van den Heuvel receives the Stairway to Impact Award from Dutch Research Council NWO. He receives this prize for the development of the BabyChecker, a smartphone application that allows midwives to make ultrasounds during pregnancies.read more
Villa Joep Research Grant for Radiotherapy & OncoImmunology (ROI) lab1 December 2021
Renske van den Bijgaart and Gosse Adema from the Radiotherapy & OncoImmunology laboratorium in collaboration with the Prinses Maxima Center received a grant from Villa Joep of 410k Euro.read more
Participating in cancer research among people with intellectual disabilities30 November 2021
Thanks to the support of the Maarten van der Weijden Foundation research was carried out into the participation of people with intellectual disabilities in (population) screening for cancer.read more